Plasma Levels of Plasminogen Activator Inhibitor Type 1 and Vitronectin in Children With Cancer.
BACKGROUND
The plasminogen activator system controls intravascular fibrin deposition; besides, it also participates in a wide variety of physiologic and pathologic processes, including cancer.


METHODS
In this study, we examined the levels of plasminogen activator inhibitor 1 (PAI-1) and vitronectin in 32 newly diagnosed pediatric patients with malignancies, determined by enzyme-linked immunosorbent assay between January 2009 and January 2010 and compared them to 35 age-matched healthy children, using SPSS 16.0 software.


RESULTS
The mean level of PAI-1 was 23.02 ± 15 (8.2-71.19) ng/mL and vitronectin was 83.10% ± 23.77% (12%-126%) in the tumor group. Thirty-five healthy children in the same age range were enrolled in the control group. The levels of PAI-1 and vitronectin were 23.63 ± 10.44 (11.67-58.85) ng/mL and 85% ± 20.85% (39%-126%), respectively. No significant difference was found between the 2 groups by independent sample t-test (P = .86 and P = .69).


CONCLUSIONS
This is a preliminary study done in children with malignancies, investigating PAI-1 and vitronectin. Further study is needed, including larger trials and tumor tissue with histopathological examination as in adults.
Pediatric Hematology and Oncology Clinic, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey deniztugcu@superonline.com.
D
D
Tugcu
Pediatric Hematology-Oncology, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
O
O
Devecioglu
Pediatric Hematology-Oncology, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
A
A
Unuvar
Biochemistry, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
H
H
Ekmekci
Biochemistry, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
O B
OB
Ekmekci
Pediatric Hematology-Oncology, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
S
S
Anak
Pediatric Hematology-Oncology, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
G
G
Ozturk
Pediatric Hematology and Oncology Clinic, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
A
A
Akcay
Pediatric Hematology and Oncology Clinic, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
G
G
Aydogan
D000328:Adult; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D009369:Neoplasms / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D019096:Vitronectin / Q000097:blood*
D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D019096:Vitronectin
PAI-1; pediatric cancer; vitronectin